These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12939639)

  • 1. Mouse B7-H3 induces antitumor immunity.
    Sun X; Vale M; Leung E; Kanwar JR; Gupta R; Krissansen GW
    Gene Ther; 2003 Sep; 10(20):1728-34. PubMed ID: 12939639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.
    Rafiee M; Kanwar JR; Berg RW; Lehnert K; Lisowska K; Krissansen GW
    Cancer Gene Ther; 2001 Dec; 8(12):974-81. PubMed ID: 11781660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
    Chapoval AI; Ni J; Lau JS; Wilcox RA; Flies DB; Liu D; Dong H; Sica GL; Zhu G; Tamada K; Chen L
    Nat Immunol; 2001 Mar; 2(3):269-74. PubMed ID: 11224528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
    Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
    Cancer Gene Ther; 2001 Oct; 8(10):719-27. PubMed ID: 11687895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
    Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
    Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogene therapy against mouse leukemia using B7 molecules.
    Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
    Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer.
    Lupu CM; Eisenbach C; Lupu AD; Kuefner MA; Hoyler B; Stremmel W; Encke J
    Oncol Rep; 2007 Sep; 18(3):745-8. PubMed ID: 17671729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble mouse B7-H3 down-regulates dendritic cell stimulatory capacity to allogenic T cell proliferation and production of IL-2 and IFN-gamma.
    Xu J; Huang B; Xiong P; Feng W; Xu Y; Fang M; Zheng F; Gong F
    Cell Mol Immunol; 2006 Jun; 3(3):235-40. PubMed ID: 16893505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.